BYSI BeyondSpring
- 2.630
- -0.080-2.95%
- 2.500
- -0.130-4.94%
BeyondSpring News
BeyondSpring (NASDAQ:BYSI) Shareholders Have Earned a 141% Return Over the Last Year
Express News | BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics
Express News | BeyondSpring Reports FY23 Loss Per Share Of $(0.54) Vs. $(0.85) Last Year
Press Release: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.
BeyondSpring Files 2023 Annual Report on Form 20-F
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer
Express News | Beyondspring Provides Business Update and Reports Year End 2023 Financial Results
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment
BeyondSpring (BYSI) said Monday that the first patient has been dosed in a phase 2 investigator-initiated trial of pembrolizumab, plinabulin plus etoposide/platinum for first-line extensive-stage smal
BeyondSpring Announces First Patient Dosed With Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring Inc. (NASDAQ: BYSI) today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring's lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350].
BeyondSpring Announces Executive Leadership Change
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersPsyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (
BeyondSpring, EnVVeno Medical, Aptorum Group Among Healthcare Movers
BYSI, PHUN and DTSS Among Pre-market Losers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) shares increased by 69.4% to $1.46 during Wednesday's pre-market session. The market value of their outstanding shares is at $31.9 million. Creative Medical Tech (NA
Top Premarket Decliners
Entravision Communications (EVC) shares slumped 50% Wednesday premarket after the company posted a wider Q4 loss. Thor Industries (THO) shares fell 17% after reporting weaker fiscal Q2 financial resul
Individual Investors Who Hold 59% of BeyondSpring Inc. (NASDAQ:BYSI) Gained 125%, Insiders Profited as Well
Key Insights Significant control over BeyondSpring by individual investors implies that the general public has more power to influence management and governance-related decisions 41% of the business
EYEN, BYSI and FENG Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersSunshine Biopharma (NASDAQ:SBFM) stock rose 142.3% to $0.11 during Tuesday's regular session. The company's market cap stands at $5.9 million. Ocean Biomedical (NASDAQ:OCEA) shares rose 54.65%
BeyondSpring Regains Nasdaq Compliance as Price Surges Above $1
BeyondSpring Regains Compliance With Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbrea
Analysis
Price Target
No Data
